कंपनी का अवलोकन
Pharvaris N.V. operates as a late-stage biopharmaceutical entity dedicated to the research, development, and commercialization of therapeutic interventions for rare diseases characterized by unmet medical needs, specifically within the domains of angioedema and other conditions mediated by bradykinin. The corporation utilizes deucrictibant, a proprietary small molecule functioning as a bradykinin B2-receptor antagonist, as its primary therapeutic asset for addressing these specific pathological mechanisms. This organization functions within the broader Healthcare sector, specifically categorized under the Biotechnology industry, a classification that signifies its focus on discovering and manufacturing new biological drugs rather than established pharmaceutical products. The company's current market capitalization stands at $1.78B, while its reported annual revenue and total employee count are recorded at N/A and 118 employees, respectively. The market cap figure of $1.78B suggests that the valuation is driven primarily by future potential and intellectual property rights rather than current cash flow generation, which is a common characteristic for biotechnology firms in the late-stage development phase where significant capital is allocated toward clinical trials before widespread commercialization.
वित्तीय स्वास्थ्य
The financial statements for Pharvaris N.V. reveal a Net Income of $-163,719,488 and an EBITDA of $-167,259,872 over the trailing twelve months, indicating substantial operating losses that are typical for biotech companies scaling their clinical pipelines. The absence of reported Revenue (TTM) and the resulting 0.0% Gross Margin, Operating Margin, and Profit Margin highlight a cost structure where expenses significantly outweigh current sales, reflecting the heavy investment required in R&D and clinical operations before product launch. Consequently, the company's Free Cash Flow stands at $-76,153,248, which demonstrates a consumption of cash reserves to fund ongoing development activities rather than a generation of surplus liquidity from operations. Despite these losses, the balance sheet maintains a Cash position of $329.29M against total Debt of $578,657, resulting in a Debt to Equity ratio of 0.18. This specific debt level relative to equity suggests a balance sheet that is not heavily leveraged, providing a buffer against the cash burn rate associated with drug development. The Current Ratio is calculated at 12.86, a metric that indicates an exceptionally strong short-term liquidity position, ensuring the company can comfortably meet its immediate obligations with its available current assets. Furthermore, the Return on Equity is reported at -53.8% and the Return on Assets at -32.1%, figures that reveal management is currently deploying capital to generate losses in pursuit of future value creation rather than immediate profitability, a standard strategic posture for entities in the biotechnology sector focused on long-term therapeutic breakthroughs.
मूल्यांकन आकलन
The valuation metrics for Pharvaris N.V. present a Trailing P/E Ratio (TTM) as N/A due to negative earnings, while the Forward P/E is listed at -8.59, implying that the market prices the stock based on anticipated future earnings rather than historical performance. The Price to Book ratio is established at 4.93, indicating that the market values the company at nearly five times its book value, which often reflects the high intrinsic value assigned to intangible assets such as intellectual property and clinical trial data that are not fully captured on the balance sheet. Alternative valuation measures including the Price to Sales ratio (N/A) and an EV/EBITDA of -8.66 further illustrate the reliance on non-earnings-based metrics for assessing the firm's worth in the absence of positive profitability. The stock's price volatility is bounded by a 52-Week High of $29.80 and a 52-Week Low of $11.51, placing the current trading position somewhere within this wide range depending on the specific day's market close. The Beta value is recorded at -2.71, a negative coefficient that signifies the stock price moves inversely to the broader market, exhibiting extreme volatility where market declines can paradoxically drive the stock price up and vice versa, presenting a unique risk profile distinct from typical market-correlated assets.
Growth & Income
The growth metrics for Pharvaris N.V. show a Revenue Growth (YoY) of N/A and an Earnings Growth (YoY) of N/A, as the company has not yet achieved significant commercial revenue to support year-over-year comparison calculations. Since the company does not pay dividends, with a Dividend Yield of N/A and a Payout Ratio of 0.0%, it follows a capital allocation strategy where all available earnings and cash flow are reinvested directly into research, development, and the commercialization of its bradykinin-targeting therapies rather than distributed to shareholders. The absence of a payout ratio confirms that the company prioritizes funding its clinical pipeline and operational expansion over providing immediate income returns to investors. Overall, the growth and income profile of Pharvaris N.V. is defined by a complete reinvestment strategy aimed at achieving future profitability rather than delivering current financial returns or dividend income.